In patients with isolated optic neuritis (ON), the presence of antibodies to aquaporin 4 (AQP4) has diagnostic and prognostic value. In the same clinical setting, the significance of antibodies to myelin-oligodendrocyte glycoprotein (MOG) or the glycine receptor α1 subunit (GlyR) is unclear.
1
However, after extensive diagnostic workup and prolonged follow-up, some patients are diagnosed as having idiopathic monophasic or recurrent isolated ON. 2 The presence of autoantibodies may help to differentiate these disorders. As many as 20% of patients with recurrent ON have antibodies to aquaporin 4 (AQP4), and their presence conveys the risk for developing transverse myelitis and a poor outcome. 3 A subset of patients with NMO or suspected limited forms (including ON) without AQP4 antibodies have antibodies to myelinoligodendrocyte glycoprotein (MOG). 4 Patients with MOG antibodies seem to have a better outcome than those with AQP4 antibodies. 5, 6 In a previous study examining the presence of antibodies to the glycine receptor α1 subunit (GlyR) in patients with stiff person syndrome, McKeon and colleagues 7 found among 100
control individuals a patient with a 2-year history of visual deficits (visual acuity [VA] , 20/400) and bilateral optic atrophy in association with GlyR antibodies. Despite the prolonged duration of symptoms, the VA improved after a trial of corticosteroids (20/100 OD and 20/150 OS). 7 Since then, several of us (E.M.-H., M.S., and A.S.) have seen another patient with bilateral progressive inflammatory optic neuropathy and GlyR antibodies, and similar observations have been made by other investigators. 8 These findings suggested that GlyR antibodies may be associated with ON as relevant pathogenically related antibodies or as an epiphenomenon. We report herein our experience with 51 patients who presented with unilateral or bilateral, severe, or recurrent isolated ON, a clinical profile that is usually suspected of being related to AQP4 antibodies. 1, 3 We tested serum or cerebrospinal fluid (CSF) samples from each patient systematically for all 3 antibodies (AQP4, MOG, and GlyR), with the goal of determining their frequency and the clinical and prognostic correlates.
Methods

Patients and Samples
We obtained written informed consent for this study from all patients, and the study was approved by the review board of the Hospital Clínic, University of Barcelona, Barcelona, Spain. We included patients with the following criteria: (1) 
Cell-Based Assays
For the detection of GlyR antibodies, we used a live cell-based assay. In brief, HEK293 cells were transfected with a plasmid (pRK5) containing the human GlyR α1 subunit complementary DNA, as reported. 13 The Coverslips were then applied with mounting medium (Vectashield H-1200; Vector Laboratories) and examined under a fluorescence microscope using a commercially available imaging system (Axiovision; Zeiss). All positive samples and 11 randomly selected negative samples underwent similar testing with live cells at room temperature and at 4°C to determine whether changes in the temperature of incubation modified the immunostaining results. Antibodies to AQP4 and MOG were similarly examined using live HEK293 cells transfected with the AQP4-M23 isoform or the full-length MOG C-terminal fused to enhanced green fluorescent protein, as reported.
14 For detection of AQP4
antibodies, serum samples were used at a dilution of 1:20; and for MOG antibodies, 1:160. Cerebrospinal fluid samples were used at a dilution of 1:2. The titer of GlyR and MOG antibodies was obtained by serial dilutions of samples until the reactivity was no longer visible.
Results
Demographics and General Clinical Features
The median age of the patients at symptom onset was 28 (range, 5-65) years; 36 patients (71%) were female. The initial episode was severe unilateral ON in 13 patients (25%), severe bilateral ON in 14 patients (27%), nonsevere bilateral ON in 8 patients (16%), and nonsevere unilateral in 16 (31%). The findings of magnetic resonance imaging of the brain at symptom onset were normal in 36 patients (71%) and had nonspecific abnormalities in 15 patients (29%). The CSF studies available in 37 patients showed CSF-specific IgG oligoclonal bands in 3 (8% 9 and 2 relapses of ON), and 7 patients had conversion to NMO or NMO spectrum disorder. Of these 7 patients, 3 had recurrent ON, 2 had episodes of transverse myelitis, 12 1 had an episode of brainstem dysfunction, and 1 had bilateral and severe monophasic ON.
Antibody Findings
Serum antibodies were detected in 23 patients (45%). Of these, 10 patients had MOG antibodies, 6 patients had AQP4 antibodies, and 7 patients had GlyR antibodies (3 with concurrent MOG antibodies and 1 with concurrent AQP4 antibodies) (Figure) . The change of temperature during the incubation with patients' samples did not modify the results. Paired serum and CSF samples were available from 4 patients, of whom 1 had MOG antibodies in serum and CSF and 1 had concurrent MOG and GlyR antibodies only in serum. In the remaining 2 patients, both samples were negative.
Among the 48 controls with NMO, 37 (77%) had AQP4 antibodies, 4 (8%) had MOG antibodies, 2 (4%) had AQP4 antibodies concurrent with MOG antibodies, and 5 (10%) were seronegative. None of the controls with NMO had GlyR antibodies. Among the 64 controls with MS, 5 (8%) had GlyR antibodies, including 3 with relapsing remitting MS, 1 with a clinically isolated syndrome of myelitis, and 1 with primary progressive MS. The CSF samples of 4 of these 5 patients were available for study, and all were negative for GlyR antibodies. All controls with MS were negative for AQP4 and MOG antibodies. None of the 30 healthy individuals had detectable antibodies.
Clinicoimmunologic Correlates
The 4 patients with 2 antibodies were excluded from the analysis, and we compared the seronegative patients (n = 28), the patients with MOG antibodies only (n = 10), those with APQ4 antibodies only (n = 6), and those with GlyR antibodies only (n = 3) ( Table 1 ). The only significant differences found among subgroups were the final visual scores (P = .04, Kruskal-Wallis test) and the use of long-term immunosuppressive therapy (P < . Other differences did not reach statistical significance on multiple comparisons, probably owing to the low number of patients in each subgroup. However, compared with the patients with AQP4 antibodies, those with MOG antibodies were less frequently female (5 of 10 [50%] vs 6 of 6 [100%]) and were younger (median age, 18 vs 44 years). No differences were found in the frequency of severe or bilateral first episodes of ON or recurrent ON. The AQP4 antibodies were not detected in children.
The clinical features of the 7 patients with GlyR antibodies are shown in Table 2 . Median age was 27 (range, 11-38) years; 5 of these (71%) were female. Among the 3 patients with GlyR antibodies alone, 2 had idiopathic isolated ON (recurrent in one and monophasic bilateral in the other) and 1 experienced conversion to MS. 9 The 3 patients with GlyR antibodies concurrent with MOG antibodies had idiopathic recurrent isolated ON, and the patient with concurrent AQP4 antibodies experienced conversion to definite NMO. 12 At the last 
Discussion
This study shows that 45% of patients with new-onset unilateral or bilateral, severe, or recurrent ON, in the absence of clinical and magnetic resonance imaging findings outside the optic nerves, had antibodies to MOG, AQP4, or GlyR. Moreover, when one considers the patients who at the last follow-up retained the diagnosis of idiopathic isolated ON, 15 of 43 (35%) had MOG, GlyR, or both antibodies. The identification of autoantibodies was important for 2 reasons. First, it showed the presence of specific autoimmune mechanisms, and second, it had clinical and prognostic implications. Indeed, compared with patients with AQP4 antibodies, those with MOG antibodies were younger and, despite the similar frequency of severe or bilateral first episodes of ON or recurrent ON, had a better visual outcome. Some of these antibody-associated features are similar to those reported in the context of NMO or NMOrelated syndromes. For example, in patients with NMO or limited forms of NMO, the presence of MOG antibodies has been shown to be associated with a better outcome than the presence of AQP4 antibodies. 5, 6 In another study examining the presence and prognostic value of AQP4 antibodies in patients with recurrent ON, seropositive patients had a worse final visual score than that of seronegative patients, similar to our study. 3 The more frequent use of long-term immunosuppressive therapy in patients with AQP4 antibodies likely is explained by the availability of this antibody in routine clinical tests (MOG and GlyR antibodies were examined retrospectively) and the awareness that detection of AQP4 antibodies is associated with a high risk for accumulating disability. We did not find AQP4 antibodies in children with ON 15 ; this finding is in contrast to that of the studies of children with NMO, in whom the frequency of AQP4 antibodies is similar to that of the adults. 16 However, our study focused on isolated ON, leading to the exclusion of patients with AQP4 antibodies that frequently occur with additional symptoms or radiologic findings beyond the optic nerves. 17 To our knowledge, the presence of GlyR antibodies has not been investigated previously in patients with isolated ON. In the present study, 7 patients with ON (14%) had GlyR antibodies, and these were associated with other antibodies in 4 patients (57%). Moreover, GlyR antibodies were identified in 5 controls with MS (8%). These patients represented all the clinical phenotypes of MS, and none of them developed symptoms of stiff person syndrome or progressive encephalomyelitis with rigidity and myoclonus. The GlyR antibodies are abundantly expressed in inhibitory synapses of the brainstem, spinal cord, and retina, and the association with demyelinating diseases has been suggested in other reports, including 2 patients with NMO 18 and a child with transverse myelitis and deep brain white matter abnormalities. 19 A pathogenic link among GlyR antibodies, ON, and demyelinating disorders has not been established, but these antibodies can occur in several different disorders. Indeed, in a recent study of patients with cerebellar ataxia and glutamic acid decarboxylase 65 antibodies, 20 GlyR antibodies were identified in 4 of 34 patients (12%), and their presence did not correlate with any specific clinical feature. These findings are in contrast to a recent report 8 suggesting a high specificity of GlyR antibodies for progressive encephalomyelitis with rigidity and myoclonus; however, the control samples used in that report included only serum samples from patients with N-methyl-D-aspartate receptor-and AQP4 antibody-associated syndromes or CSF samples from patients with MS. In our study, the persistence of unchanged titers of GlyR antibodies in 4 of the 5 patients 
